RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Free Report) has earned an average recommendation of “Hold” from the ten brokerages that are currently covering the stock, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $18.17.
Several brokerages recently issued reports on RAPT. HC Wainwright reissued a “neutral” rating on shares of RAPT Therapeutics in a research note on Tuesday, August 20th. UBS Group lowered their target price on RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating for the company in a report on Monday, September 9th.
Check Out Our Latest Analysis on RAPT Therapeutics
Institutional Trading of RAPT Therapeutics
RAPT Therapeutics Price Performance
Shares of NASDAQ RAPT opened at $2.01 on Thursday. RAPT Therapeutics has a 1-year low of $1.73 and a 1-year high of $27.35. The business’s 50 day moving average is $2.31 and its two-hundred day moving average is $4.45. The stock has a market capitalization of $70.15 million, a P/E ratio of -0.65 and a beta of 0.33.
RAPT Therapeutics (NASDAQ:RAPT – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.03. As a group, equities research analysts anticipate that RAPT Therapeutics will post -2.73 earnings per share for the current fiscal year.
About RAPT Therapeutics
RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Further Reading
- Five stocks we like better than RAPT Therapeutics
- The Most Important Warren Buffett Stock for Investors: His Own
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- With Risk Tolerance, One Size Does Not Fit All
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- Are Penny Stocks a Good Fit for Your Portfolio?
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.